Objective: Although women are the most common recipients of weight loss surgeries for the amelioration of the comorbidities of obesity, few studies have addressed the efficacy of these procedures with specific attention to reproductive stage. Here we ask in a rodent model of vertical sleeve gastrectomy (VSG) whether improvements to metabolic health are realized in women having received surgical menopause. Specifically we were interested in knowing whether rats made menopausal through surgical means would exhibit persistent hepatic steatosis as reported in previously pregnant, freely cycling female VSG rats or if it is resolved as reported in male VSG rats.
W omen aged 40 to 59 years have the highest prevalence of obesity in comparison to either males of the same age or females of other age categories. 1 This age bracket encompasses women who are naturally transitioning to menopause which begins between 45 and 55 years and is completed by approximately 60 years. Menopause is the permanent cessation of menstrual periods that occurs with ageing. Menopause can also be induced by surgical removal of the ovaries, and it may occur as a side effect of chemotherapy or radiation treatments. Menopause results in part from a reduction in both estrogen and progesterone production by the ovaries. Because many body tissues are estrogen-responsive, the perimenopausal sequelae are substantial and diverse, but a common effect is weight gain. The perimenopausal side effects include vasomotor symptoms such as sweats and hot flashes, vaginal dryness, sexual dysfunction, urinary incontinence, sleep disturbances, memory loss, depression, headaches, fatigue, joint pain, and weight gain. With the loss of a protective effect of estrogen on diverse body systems, postmenopausal women are at increased risk for various components of metabolic syndrome such as heart disease, obesity, diabetes, and dyslipidemia.
Bariatric surgery for long-term body weight loss and resolution of the comorbidities of obesity has gained popularity in the last decades. 2, 3 The vast majority of recipients of bariatric surgeries are women (>80%) 4 of whom approximately half are of the peri/postmenopause age. 5 Vertical sleeve gastrectomy (VSG) resects 80% of the stomach, creating a tube linking the esophagus to the duodenum. Because of the effectiveness and relative simplicity of VSG surgery in comparison to the gold standard surgery, Roux-en-Y gastric bypass (RYGB), which is riddled with a variety of potential complications, VSG is now on the rise in the United States. 6, 7 Many clinical indices show improvement with VSG that rivals the outcomes of RYGB. For example, the reported loss of 60% to 65% of excess body weight after VSG 8, 9 is similar to RYGB. 8 The remission of comorbidities, such as type-2 diabetes mellitus and hyperlipidemia, is similar for VSG with respect to RYGB. Death due to myocardial infarction and cardiovascular death are reduced by approximately 50%. 10 Overall risk for cancer mortality is reduced. 11 With respect to nonalcoholic fatty liver disease, no studies to date have reported liver biopsies from patients having received VSG comparing perioperative and postsurgical hepatic histology and steatosis. Numerous studies suggest that hepatic steatosis, fibrosis, and inflammation are significantly improved after RYGB. [12] [13] [14] [15] [16] These findings are not universal, however, because one study showed an improvement in steatosis but no histologic improvement of fibrosis, 17 a condition whose longterm damage may cause increased mortality risk. 18 Although numerous clinical improvements resulting from both RYGB and VSG are promising, stratified analyses for the efficacy of each of these clinical parameters by age and reproductive status are sparse. 19 This is particularly true with respect to pre-, peri-and postmenopausal women who have unique metabolic issues.
Rodent models of VSG and RYGB have demonstrated many of the beneficial outcomes to human bariatric patients such as decreased body weight through fat loss, improvements in glucose tolerance, and metabolic hormone changes. [20] [21] [22] [23] [24] [25] Rodent models have also revealed at least one negative outcome of VSG surgery that is yet to be reported in the human literature. Primiparous female rats exhibited a worsening of hepatic steatosis post-VSG, 26 whereas male rats showed a reduction of lipids in the liver. 6 Overall, only one report has specifically addressed the impact of bariatric surgery in a rodent model of menopause. RYGB was used in a surgical model of menopause, and the interaction of estradiol replacement and surgical weight loss was reported. 27 No work has been reported about the effect of VSG in a menopause model. The goal of this study is to determine whether VSG is sufficient to produce improvements in global metabolic parameters in a surgical model of menopause, in comparison with previously reported indices in males and reproductively intact females. We also sought to determine whether hepatic steatosis would be improved, as in male rats, or persist and worsen, as in postpartum female rats. Female Long-Evans rats were ovariectomized (OVX) and allowed to recover for 3 weeks on standard chow and then placed on a high-fat diet (HFD) for an additional 3 weeks. At this point the animals received either sham surgery or VSG. After 5 weeks of surgical recovery while being maintained on HFD, we interrogated measures of body mass, food intake, body composition, glucose tolerance, and circulating hormones. We focused on liver integrity, hepatic gene expression, lipid levels, and liver mitochondrial function.
METHODS

Animals
All procedures for animal use complied with the Guidelines for the Care and Use of Laboratory Animals by the National Institutes of Health and were reviewed and approved by the University of Mississippi Medical Center Institutional Animal Care and Use Committee.
Female Long-Evans rats (200-225 g) (Harlan, Indianapolis, IN) (N ¼ 30) were initially multiply housed and maintained in a room on a 12/12-hour light/dark cycle at 258C and 50% to 60% humidity with ad libitum access to water and standard chow (#8640, Envigo, 3.0 kCal/g; 17% fat, 54% carbohydrate, 29% protein). After 1 week of acclimatization to the vivarium, female rats received a bilateral ovariectomy. Animals remained on standard chow for 3 weeks and then were switched to palatable HFD (#D03082706, Research Diets, New Brunswick, NJ, 4.54 kCal/g; 40% fat, 46% carbohydrate, 15% protein) for 3 weeks before weight loss surgery and for the remainder of the study. Animals were assigned in a counterbalanced fashion by body weight to receive either sham-VSG or VSG surgery (N ¼ 12, 18). The animals therein were assigned as either OVX-obese or OVX-VSG. Animals were singly housed thereafter and continued on the study for an additional 6 weeks postsurgery. Animals were euthanized by conscious decapitation for tissue harvest, trunk blood, and isolation of liver mitochondria (final N ¼ 12 [sham], 9 [VSG]). Reasons for exclusion or loss of animals include postoperative complications of VSG surgery. Surgical success was similar to previous published studies. 26, 28 Surgical procedures Bilateral ovariectomy Animals were given one dose of carprofen (0.10 mL of 5 mg/mL) at the time of surgery. Rats were anesthetized using isoflurane. Two small medial abdominal incisions (0.5 inches long) were made to expose the ovaries. Oviducts were tied off with sterile, absorbable suture, and ovaries removed. The muscular wall was closed with sterile sutures and the skin closed using wound clips.
Surgical weight loss preoperative care
Four days before VSG or sham-VSG surgery, body composition was assessed using an EchoMRI analyzer (Houston, TX). Animals were placed in either sham or VSG groups in a counterbalanced fashion by body weight and also taking into account body fat composition. Animals were fed Osmolite OneCal liquid diet (#00735, Abbott Laboratories, Columbus, OH), but no solid food for 24 hours before surgery.
VSG
VSG consisted of a midline abdominal laparotomy with exteriorization of the stomach. Ligaments and connective tissue were removed leaving an easily articulated stomach. The lateral 80% of the stomach was excised using an ENDO GIA Ultra Universal stapler (#EGIAUSHORT, Medtronic, Boulder, CO) coupled with an ENDO GIA Auto Suture Universal Articulating Loading Unit, 45 mm-2.5 mm (#030454, Covidien, Mansfield, MA). A gastric tube in continuity with the esophagus thus remained. This gastric sleeve was then reintegrated into the abdominal cavity, and the abdominal wall was closed in layers using 3-0 coated vicryl suture (#J904, Ethicon, Cincinnati, OH).
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Sham-VSG
An abdominal laparotomy was performed. Light manual pressure was applied to the exteriorized stomach and then the abdomen was closed in layers as described above.
Postoperative care
After surgery, all rats received care for 2 days, consisting of once-daily subcutaneous injections of 5 mL saline and carprofen (0.10 mL of 5 mg/mL dose) and twice-daily subcutaneous injections of Buprenex (0.10 mL of 0.3 mg/mL dose). Animals were maintained on Osmolite (#00735, Abbott Laboratories) until food was returned 3 days after surgery.
Body weight, composition, and food intake Body weights were measured weekly. After the weight loss surgery, animals were weighted daily for the first 7 days and then weekly thereafter. Body lean and fat mass composition was analyzed using Echo Magnetic Resonance Imaging (EchoMedical Systems, Houston, TX) at the start of the study and at 3, 6, and 11 weeks.
Glucose tolerance testing
Rats were fasted for 6 hours after the onset of the light cycle. Baseline tail vein blood glucose was measured by Accu-Chek Aviva Plus glucometer and glucose strips (Roche, Indianapolis, IN). Animals were then dosed with 50% dextrose (1.5 g/kg body weight) intraperitoneally at time t ¼ 0 minute and subsequently blood glucose measured at t ¼ 15, 30, 45, 60, and 120 minutes postinjection. Tail vein blood was also collected in heparinized tubes for insulin determination at 0 and 15 minutes. Insulin measurements were made using an Insulin ELISA (#90060, Crystal Chem Inc, Downers Grove, IL). Glucose and insulin measurements were made in duplicate.
Insulin tolerance test
Rats were fasted for 6 hours after the onset of the light cycle. Baseline blood glucose measurements were made (t ¼ 0 min) and then animals dosed with Humulin-R (#HI-213, Eli Lilly and Company, Indianapolis, IN) (0.5 U/kg body weight), and tail vein measurements of blood glucose were made using the glucometer at t ¼ 15, 30, 45, and 60 minutes.
Tissue harvest
At postoperative days 42-44 (POD with respect to VSG or sham surgery) animals were euthanized by conscious decapitation starting at 6 hours after the onset of the light cycle.
Isolation of intact liver mitochondria
Hepatic mitochondria were isolated using a modified protocol of published methods. 29 Each freshly excised rat liver was washed in 20 to 30 mL of ice-cold 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.2, 0.3 M sucrose, 0.2 mM ethylenediaminetetraacetic acid (EDTA; Health Service Executive, Ireland); the liver was cut into 1-to 2-g sections and the fluid was discarded. The liver sections were minced with a razor for 5 minutes on an ice-cold plastic surface in the presence of 1 mL HSE and then homogenized for 10 strokes using a loose-fitting glass Dounce homogenizer (Sigma-Aldrich Corp, St. Louis, MO) in 5 mL HSE containing 0.1 mM phenylmethylsulfonylfluride (PMSF) and 1 mg/mL fatty acid-free bovine serum albumin (BSA) (Sigma). The homogenate was split into microcentrifuge tubes and cellular debris was pelleted by centrifugation at 800 Â g for 10 minutes at 48C and the supernatants containing mitochondria were recovered. Mitochondria were then pelleted by centrifugation at 8,500 Â g for 10 minutes at 48C. The supernatants were discarded, the pellets were gently resuspended using a 1 mL pipettor and pelleted again at 8,500 Â g for 10 minutes at 48C. Pellets were combined and resuspended in a total volume of 0.5 to 1.0 mL of 220 mM mannitol, 70 mM sucrose, 5 mM Mops, and pH 7.4. The protein concentration was determined using the BioRad DC Protein assay.
Assay for changes in the content of mitochondria in liver
Using a portion of the total liver homogenate, prepared as above, citrate synthase activity was measured spectrophotometrically using the Citrate Synthase Assay Kit (#CS0720, Sigma), whereas the protein concentration of the homogenate was determined using the BioRad DC Protein assay (#5000111, Bio-Rad).
Measurements of intact mitochondrial function
Rates of O 2 consumption by intact liver mitochondria were measured using an Oroboros Oxygraph at 258C. The 2 mL assay mixture contained 50 mM Mops, 5 mM KH 2 PO 4 , 100 mM KCl and 1 mM ethylene glycol-bis(b-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), pH 7.4, and mitochondria containing 0.1 to 0.5 mg protein. In separate experiments, either 20 mM glutamate plus 5 mM malate or 40 mM palmitoyl carnitine plus 5 mM malate was added to obtain the rate of State 2 respiration. Adenosine diphosphate was added to 1 mM for State 3 respiration, which is proportional to the rate of adenosine triphosphate (ATP) synthesis. State 4 respiration was determined by inhibiting ATP synthase with 5 mM oligomycin, and the rate of uncoupled respiration was obtained after adding the weak acid uncoupler carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) to 1 mM. The respiratory control ratio (RCR) is the rate of State 3 divided by the rate of State 4.
Preparation of open, washed mitochondrial membranes
Mitochondrial membranes were prepared by pelleting 0.2 to 0.4 mL intact mitochondria at 8,500 Â g for 10 minutes at 48C, followed by resuspension in an equal volume of 50 mM Tris, pH 7.4. The suspension was frozen in liquid nitrogen and thawed rapidly for two cycles, centrifuged as above and resuspended in an equal volume of 50 mM Tris, pH 7.4. Centrifugation and resuspension in Tris buffer was repeated. Protein concentrations were determined using the BioRad DC Protein assay.
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Measurements of whole chain electron transfer activity
Rates of electron transfer from nicotinamide adenine dinucleotide þ hydrogen (NADH)!O 2 and succinate!O 2 were measured as O 2 consumption using the Oroboros Oxygraph. Each assay was performed at 258C in 2 mL of 50 mM Tris, pH 7.4, 39.6 mM KCl, 40 mM horse heart cytochrome c, and mitochondrial membranes (MM) containing 0.1 to 0.2 mg protein. Electron transfer from NADH!O 2 was initiated by the addition of NADH to 400 mM and succinate!O 2 by the addition of 20 mM succinate.
Complex I activity was measured at 258C by monitoring the oxidation of NADH at 340 nm (e ¼ 6.22 mM À1 cm À1 ) using a Hitachi U-3000 spectrophotometer. The assay mixtures contained 50 mM Tris, pH 7.4, 39.6 mM KCl, 200 mM CoQ 1 , 3 mM potassium cyanide (KCN), 5 mM antimycin A, and 0.1 to 0.2 mg MM. The reaction was started by the addition of NADH to 100 mM.
Complex IV activity was measured in the Oroboros Oxygraph in 50 mM Tris, pH 7.4, 39.6 mM KCl, 3 mM ascorbate, 0.3 mM N,N,N 0 ,N 0 -tetramethyl-p-phenylenediamine (TMPD), 40 mM horse heart cytochrome c, 5 mM myxothiazol, and 5 mM antimycin A. The reaction was initiated by the addition of MM containing 0.1 to 0.2 mg protein. The slow rate of nonenzymatic reduction of O 2 by ascorbate/TMPD/cytochrome c was subtracted from all rates obtained after the addition of MM.
For the measurements of intact mitochondrial function, we examined intact mitochondria from three sham rats and four VSG rats (all chosen at random), and we performed each of the assays twice. For the measurements of citrate synthase activity, whole chain electron transfer activity, complex I activity, and complex IV activity, we examined open, washed MM from eight sham rats and five VSG rats, and we performed each assay twice.
Measurements of analytes
The following analytes were measured according to the manufacturer's specifications: triglycerides (#T7532-120, Fisher Scientific, Middletown, VA), cholesterol (#T7-120, Fisher Scientific), alanine aminotransferase (ALT) (#A7526-150, Fisher Scientific), aspartate aminotransferase (AST) (#A7561-150, Fisher Scientific), leptin (#MOB00, R & D System, Minneapolis, MD), estradiol (#DSL-4800, Beckman Coulter, Danvers, MA), testosterone (#DSL-4900, Beckman Coulter), insulin (#80558, Crystal Chem Inc, Downers Grove, IL) and progesterone (#90060, Crystal Chem Inc), and c-reactive protein (#1010, Alpha Diagnostics International, San Antonio, TX). Samples were measured in duplicate in each assay.
Hepatic triglyceride determination
Liver triglycerides were measured using 100 mg of liver tissue and Pointe Scientific Triglyceride reagent set (#T7532-120) according to manufacturer's specifications. The sample was measured in duplicate.
RNA processing and real-time PCR
Tissue was flash frozen on dry ice and then stored at À808C until further processing. Hepatic RNA was extracted using a QIAGEN miniprep RNA kit (QIAGEN, Inc, Valencia, CA), and complementary DNA was transcribed using an iScript complementary DNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). Quantitative polymerase chain reaction (PCR) was performed on a BioRad CFX96 Touch Real-Time PCR Detection System using TaqMan inventoried gene expression assays (Life Technologies, Foster City, CA). The following primer/probes were used: acyl-coenzyme A amino acid N-acyltransferase 1 (#Rn01772486_m1, ACNAT1), fatty acid synthase (#Rn00569117_m1, FASN), sterol regulatory element-binding transcription factor 1 (#Rn01495769_m1, SREBP1), interleukin 6 (Rn_01410330_m1, IL6), interleukin 1b (Rn00580432_m1, IL1b), carnitine palmitoyltransferase 1a (#Rn00580702_m1, CPT1a), and peroxisome proliferatoractivated receptor alpha (Rn00566193_m1, PPARa). These were used with 10 mL reaction in the following proportions: 0.5 mL primer/probe, 5 mL master mix (#Life Technologies), 2 mL of cDNA at a concentration of 50ng/mL, and 2.5 mL of nuclease free water. Each cDNA sample was run in duplicate and statistical agreement between replicates AE0.39%.
Paraffin embedding
Paraformaldehyde postfixed blocks of liver were subjected to standard paraffin embedding and then sectioned at 5 mm on to glass slides and processed for standard hematoxylin and eosin (H&E) stain.
Tissue lipid staining
For lipid staining, 10 mm paraformaldehyde postfixed liver sections were rinsed with 10% neutral buffered formalin, stained with Oil Red O for 10 minutes, and then subjected to standard hematoxylin staining and mounted on glass slides and coverslipped with an aqueous mounting media.
Statistical analyses
All statistical analyses were performed using GraphPad Prism version 6.07 (GraphPad Software, San Diego, CA). Differences between two surgeries were assessed by using paired Student's t test, unpaired Student's t test, and two-tailed distribution. To observe time-wise differences, two-way repeated measures analysis of variance (variables: surgical group and time) with Bonferroni post hoc test was used. All results are given as means AE SEM. Results were considered statistically significant when P < 0.05.
RESULTS
Changes in food intake and body mass
Female rats were OVX at 0 week and increased their body weight eating standard chow during the first 3 weeks after OVX (P < 0.001) and then again when placed on a palatable HFD for 3 weeks (6 wk) (P < 0.001) (Fig. 1A) . Body fat substantially increased during the 3 weeks after OVX (3 wk) VSG AND MENOPAUSE (P < 0.001) and then also during the 3 weeks on HFD (6 wk) (P < 0.001) (Fig. 1B) . Lean body mass significantly increased during the first 3 weeks after OVX (3 wk) (P < 0.001) and also during the 3 weeks of HFD induction (6 wk) (P < 0.001) (Fig. 1C) . At the beginning of the 7th week, all animals received either sham or VSG surgery and were therein called OVX-obese and OVX-VSG, respectively. All the animals initially lost weight within the first 7 days after either procedure (Fig. 1D) . OVX-VSG animals lost significantly more weight than the OVX-obese group during days 14 through 35 (P < 0.001) (Fig. 1D) . The average daily food intake was significantly reduced in the OVX-VSG group postsurgery starting at day 8 (P < 0.05), but it approached that of the OVX-obese group by day 35 (Fig. 1E) . Overall cumulative food intake was significantly reduced by OVX-VSG animals in comparison to OVX-obese females starting at day 3 (P < 0.05) (Fig. 1F) . Five weeks after surgery (ie, at 11 wk total), the OVX-VSG group showed significantly reduced body weight (P < 0.001) (Fig. 1A) , body fat (P < 0.001) (Fig. 1B) , but no changes in lean body mass composition as compared with before VSG surgery (Fig. 1C) .
Changes in lipid and glucose metabolism
On postoperative day 29 (POD29) animals were bled from their tail vein 1 hour after lights on, they were fasted for 24 hours and then bled again. In comparison to OVX-obese animals, OVX-VSG rats showed significantly reduced triglyceride levels before the 24 hours fast (P < 0.01) ( Table 1) , but no significant differences in ad libitum plasma cholesterol or in triglyceride levels after fasting (Table 1) .
On POD37, both groups of animals were fasted for 6 hours and then tested for blood glucose levels. No significant difference between the groups was noted (Table 1 ). An intraperitoneal glucose tolerance test performed on the 6-hour fasted rats, however, showed that the OVX-obese animals were significantly glucose intolerant in comparison to the OVX-VSG rats (P < 0.05, t ¼ 15, 30, 45, and 60 min) ( Fig. 2A) . The reduced glucose tolerance was not due to decreased blood insulin levels (Fig. 2B) . Insulin levels did increase in both groups as a result of time (P < 0.05) (Fig. 2B) . On POD42, animals were again fasted for 6 hours before an insulin tolerance test. No differences in blood glucose were measured during the insulin tolerance test among the two groups indicative of no insulin resistance (Fig. 2C) . 
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Changes in hepatic mitochondria
During POD49-52, three animals were euthanized daily in a counterbalanced fashion to allow for the isolation and assay of intact liver mitochondria approximately 6 hours into the light cycle. Whole fresh liver was excised for examination of liver mitochondrial content and mitochondrial function. Using citrate synthase activity as the marker for mitochondria, 30 the overall amount of mitochondria was found to be similar in the livers of OVX-obese and OVX-VSG animals (Fig. 3A) . Using intact mitochondria and an NADH-generating substrate (glutamate plus malate), we found no significant differences between the OVX-obese and OVX-VSG groups in the rate (State 3) and efficiency (RCR) of ATP production by liver mitochondria, or in the rate of proton leak across the inner membrane (State 4) (Fig. 3B) . Using fatty acid as a substrate (palmitoyl carnitine plus malate) (Fig. 3C ), there were likewise no significant differences in the rate of ATP synthesis (State 3), efficiency (RCR), or proton leak (State 4). The rate of uncoupled O 2 consumption using fatty acid was, however, significantly lower in mitochondria isolated from the livers of OVX-VSG rats (P < 0.05) (Fig. 3C) , indicating a decline in fatty acid oxidation capacity.
We prepared open, washed MM from intact mitochondria for further assays of electron transfer. The rate of electron transfer from succinate to O 2 was significantly increased in the livers of OVX-VSG animals (P < 0.001) (Fig. 4A) , whereas electron transfer from NADH to O 2 was not (Fig. 4B) . Assays of individual electron transfer complexes showed that this difference was not due to a decline in the activity of complex I (Fig. 4C) , rather it was apparently caused by a significant increase in the activity of complex IV (P < 0.001) (Fig. 4D) .
Changes in tissue histology, markers of liver damage, hormone levels, and gene expression
Liver histology stained by H&E showed no visual differences between groups (Fig. 5A) . Oil Red O staining showed significant reduction in lipid droplets in the OVX-VSG females in comparison to OVX-obese (Fig. 5B) . When hepatic lipids were quantified using a colormetric assay, the OVX-VSG group showed a significant reduction in liver triglycerides (P < 0.01) (Fig. 5C ). Adipose tissue histology by H&E showed visible reduction in adipocyte size in OVX-VSG rats (Fig. 6 ) that we did not quantify. This is in line with reduced overall fat mass composition by nuclear magnetic 
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resonance (Fig. 1B) . Reduced levels of leptin in circulation (P < 0.05) are associated with the overall decrease in fat mass in the OVX-VSG group (Table 1) .
ALT and AST are circulating transaminases released by necrotic hepatocytes. Circulating ALT levels were reduced in OVX-VSG rats in comparison to OVX-obese (P < 0.05) ( Table 1 ). There was also a trend toward reduced AST levels in the OVX-VSG group (P ¼ 0.07) ( Table 1) .
OVX-VSG females showed a trend toward less plasma estradiol than OVX-obese animals (Table 1) , but there was no difference in plasma testosterone or progesterone (Table 1) . We found no difference between circulating levels of C-reactive protein between the OVX-obese and OVX-VSG groups ( Table 1) .
Analyses of liver gene expression by RT-PCR showed no changes in the expression of several liver genes involved in lipid metabolism and mitochondrial biogenesis, including fatty acid synthase (FASN), a critical enzyme in fatty acid synthesis; sterol regulatory element-binding protein-1 (SREBP1), a transcription factor involved in fatty acid biosynthesis; carnitine palmitoyl transferase (CPT1a), a rate limiting enzyme of mitochondrial fatty acid b-oxidation; and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a), a regulator of mitochondrial biogenesis (Fig. 5D) . Likewise, we observed no differences in either IL6 or IL1b mRNA expression in the liver, suggesting no difference in inflammation among the two groups. We did observe a significant up-regulation of acylcoenzyme A amino acid N-acyltransferase 1 (ACNAT1) expression (P < 0.05) (Fig. 5D) , an enzyme involved in taurine conjugation of 16C fatty acids from peroxisomes and overall signaling by bile acids.
DISCUSSION
Weight changes associated with menopause and surgical menopause
Menopause results in a constellation of physiologic changes that have been well documented in human and animal models. Here we use bilateral oophorectomy (OVX) with no replacement of hormones to recapitulate the various sequelae of menopause in a rodent model. In human menopause, women gain anywhere from 2.5 kg at the low end to greater than 4.5 kg of body weight in the 3 years after the onset of menopause symptoms. 31 Rats maintained on chow diet after OVX increase in body weight substantially in the 3 weeks. 32 This study shows that the body mass gain over the intervening 3 weeks after OVX is mostly lean mass and only secondarily fat mass. Subsequent to HFD induction after week 3, the increase in body weight is primarily due to increased expansion of adipose mass.
Weight changes associated with VSG during surgical menopause
Little work has been reported about the effects of bariatric surgery in women of menopause age. One study compared laparoscopic banding with RYGB in women who were 55 to 65 years, and found no difference in efficacy to lose weight. 19 VSG was not reported in this cohort of women. In fact, this study is the first to examine fat mass and lean mass in menopausal women having received any bariatric surgery. We find that VSG is sufficient to reduce body weight in OVX female rats by approximately 11%. This is similar to the effect of VSG in freely cycling female rats, 26 but less than the 15.5% reduction of body weight observed in male rats after VSG over a similar time frame. 28, 33 The adiposity lost by OVX-VSG rats brought them back to the level of adiposity achieved directly before placement on HFD, but VSG did not impact the adiposity that was gained during the 3 weeks on standard chow after surgical OVX. The reduced body weight after VSG correlates with reduced food intake. The animals did not overeat to compensate for the body weight lost at any time. EchoMRI analysis shows that the body weight loss is fat mass and lean mass is completely preserved.
Effect of VSG on glucose metabolism VSG surgery in surgical menopause (OVX) rats was not associated with decreased blood glucose levels after fasting in comparison to OVX-obese rats, in contrast to reductions in fasting blood glucose after VSG in freely cycling females 26 and in males after VSG. 28 This may be due to differences in the degree of fasting in each of the studies. VSG surgery in the OVX rats did lead to improved glucose tolerance, as would be expected with their reduced bodyweight; this is of similar magnitude to freely cycling females that we previously reported. 26 Consistent with the finding of no change in fasting blood glucose levels, OVX-VSG rats showed no differences in fasting insulin levels as compared with obese rats without VSG. This agrees with other models using females overlaid with VSG. 26, 34 OVX-VSG rats also exhibited no difference in glucose-elicited insulin levels (t ¼ 15 min, postdextrose injection), consistent with a reproductively intact rat undergoing VSG. 34 Overt insulin resistance in rat models is not often observed after a short time on a saturated fat diet such as in this study. Therefore, it is not surprising that there is no effect on insulin sensitivity which was observed in OVX-VSG in comparison to OXV-obese. Taken together, we find that VSG surgery improves glucose tolerance in menopausal (OVX) rats, whereas baseline blood glucose levels, the glucoseelicited insulin response, and whole body insulin sensitivity were not changed.
VSG and hormone levels
In humans, reproductive hormones are thought to be affected by surgical weight loss. In males having received RYGB, estradiol levels decrease significantly, whereas total testosterone, free testosterone, and sex hormone-binding globulin increase substantially with no changes in folliclestimulating hormone and luteinizing hormone. 35 We would anticipate similar profiles in reproductive hormones in women having undergone menopause and also having received a weight loss surgery like VSG. Surprisingly, changes in hormone levels have not been documented after surgical weight loss in women who are ovulatory with normal menses or in postmenopausal women. In our surgical menopause rat model, females have low levels of estradiol due to OVX. After VSG surgery there is a trend toward even lower estradiol levels, but no changes in testosterone or progesterone. We hypothesize that VSG leads to a further decline in estradiol due to lower production of the hormone by adipose tissue as adipose mass decreases after VSG. Because we see no increase or reduction in lean body mass in VSG, it is not surprising that we do not see a change in testosterone levels.
VSG and hepatic steatosis
In previous studies in reproductively intact females, we reported increased hepatic steatosis in female rats who had received VSG and then subsequently became pregnant. 26 If this phenomenon were to be repeated in the human population it is of long-term concern to women; to date this has not been studied in humans however. In this study, we wanted to determine in a menopause model whether VSG would lead to increased hepatic steatosis, as in primiparous female rats 26 or whether VSG would lead to improvements in steatosis, as reported for male rats. 6 We found that VSG strongly lowered hepatic steatosis in surgical menopause (OVX) rats. This indicates that a decline in estradiol does not preclude an improvement in hepatic steatosis, and suggests that the increased steatosis as seen in pregnant, freely cycling female rats 26 is possibly dependent on or influenced by high estradiol levels.
VSG and liver mitochondrial function
Because mitochondria are key to metabolism, an overview of metabolic changes associated with VSG should include an examination of mitochondrial function. For example, some studies have linked hepatic steatosis with mitochondrial dysfunction. 36, 37 Because we found that VSG relieves hepatic steatosis, might the amount of liver mitochondria decline and/ or might they show a decreased capacity for fatty acid oxidation? Moreover, VSG and other bariatric surgeries alter hormonal status, which often leads to changes in mitochondrial function. Data on mitochondrial function in rat models of bariatric surgery are sparse, and the effect of VSG, in particular, has not been examined. In fact, this study, to our knowledge, is the first to examine mitochondrial function after bariatric surgery of any type in female rats.
VSG does not alter the amount of mitochondria in liver. Citrate synthase activity, which has been demonstrated to be a reliable marker of tissue mitochondrial content, 30 is the same in OVX-obese and OVX-VSG rats. Using substrate (glutamate plus malate) that drives electron transfer from NADH to O 2 , and using the fatty acid substrate palmitoyl CoA, we found no significant differences between the OVX-obese and OVX-VSG groups in the rate (State 3) and efficiency (RCR) of ATP production by liver mitochondria, or in the rate of proton leak across the membrane (State 4). We did observe a small decline in the maximal capacity to oxidize fatty acids after VSG surgery, perhaps in response to the significant loss in fat mass in the OVX-VSG group. We conclude that the hormonal and metabolic changes associated with VSG surgery do not affect the ability of liver mitochondria to produce ATP.
Although studies of mitochondria isolated from male rats after bariatric surgery have not reported on the capacity of oxidative phosphorylation to synthesize ATP, they have reported changes in the content of complex I or complex IV of mitochondria. Using blue-native gels, Guijarro et al 38 reported an approximately 40% decline in the content of complex I in skeletal muscle mitochondria after RYGB, LAWSON ET AL whereas Verbeek et al 39 reported a doubling of the content of complex I in liver mitochondria after RYGB. Our measurements of the rotenone-sensitive NADH!quinone activity of complex I show that its content remains unaltered in liver mitochondria after VSG surgery in OVX female rats. We do, however, find that VSG is accompanied by a 20% increase in the activity of complex IV, likely due to an increase in the amount of complex IV in the membrane. An increase in complex IV content has also been observed via immunoblots in male rats after bariatric surgery. Peng and Murr 40 report a 60% increase in liver complex IV after RYGB, whereas Pezeshki and Chelikani 41 report a similar increase in skeletal muscle after ileal transposition.
There exists evidence for less production of reactive oxygen species (ROS) in liver mitochondria after bariatric surgery in male rats. 39, 40 We measured the percent of electrons that ''leak'' to O 2 to produce superoxide during electron transfer from succinate to O 2 in washed MM prepared from OVX-obese and OVX-VSG female rats. In fact, superoxide production was approximately 30% lower in the OVX-VSG group, but the difference (data not shown) fell short of significance. Nonetheless, we note that the increase in complex IV activity in OVX-VSG female rats is likely to lower the production of mitochondrial ROS. Mitochondrial ROS production takes place during electron transfer as one-electron intermediates generated by complexes I and III occasionally reduce O 2 to superoxide. 42 Superoxide then goes on to form hydrogen peroxide and the potent hydroxyl radical, which causes protein carbonylation and lipid peroxidation. Increased complex IV activity, in the absence of increased complex I activity (the situation in our OVX-VSG rats), will leave the electron transfer chain of mitochondria more oxidized. This, in turn, decreases the lifetime of the O 2 -reducing intermediates in complexes I and III and lowers the production of superoxide. 43 CONCLUSIONS VSG is increasingly being sought after in women of all ages. At present approximately 40% of the total number of patients seeking bariatric surgery are women of menopause age. Our present data highlight that VSG does work successfully in a rodent model of menopause and begins to fill in the lack of knowledge about bariatric surgery with menopause. We find that VSG results in physiologic improvements in body weight, glucose tolerance, and hepatic lipids. Liver mitochondrial function is maintained, and an increase in complex IV may decrease the production of mitochondrial ROS. Furthermore, we provide evidence that the hepatic lipid steatosis observed in postpartum female rats does not occur in OVX female rats; in fact hepatic lipids are improved. Future work is necessary to determine if these results are reproducible in humans. Specific work is also required to understand liver function and the resolution of liver disease after VSG, in cohorts separated by age and reproductive status.
